Quantum Biopharma Ltd.: Form 20-F for the period ended Dec 31, 2025
Filed with the SEC on Mar 26, 2026 and accepted by EDGAR at Mar 26, 2026, 20:02 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$15.3m | ifrs-full:ProfitLossFromOperatingActivities |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$8.2m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2025-12-31 | $1.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2025-12-31 | $6.5m | ifrs-full:CurrentAssets |
| Total assets | At period end2025-12-31 | $11.2m | ifrs-full:Assets |
| Current liabilities | At period end2025-12-31 | $6.1m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2025-12-31 | $6.1m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2025-12-31 | $6.9m | ifrs-full:EquityAttributableToOwnersOfParent |
Source: SEC EDGAR, the filing index for accession 0001185185-26-001069. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.